No Data
No Data
Express News | Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Ionis Pharmaceuticals Shares Rise After Positive Results for Angelman Syndrome Drug Study
Ionis Pharmaceuticals (IONS) said Monday that results from the multiple ascending dose part of phase 1/2 study of ION582 showed consistent clinical improvement of all functional domains in patients
Express News | Ionis Pharmaceuticals: 97% Of Patients in Medium and High Dose Groups Saw Improvement in Overall Angelman Syndrome Symptoms
Express News | Ionis Pharmaceuticals Inc - to Initiate Phase 3 Development in H1 2025
Express News | Ionis Announces Positive Detailed Results From the Halos Study of Ion582 in People With Angelman Syndrome